{"add":{"path":"query=Ozempic%2520Eli%2520Lilly/published date str=2023-12-07/1-ee5c5e5b-1208-47ad-8fa1-99d2d50bb2d9-0.parquet","partitionValues":{"query":"Ozempic Eli Lilly","published date str":"2023-12-07"},"size":158875,"modificationTime":1701916432900,"dataChange":true,"stats":"{\"numRecords\": 1, \"minValues\": {\"title\": \"Fezolinetant Changes Menopause Management, with JoAnn ... - MD Magazine\", \"description\": \"Fezolinetant Changes Menopause Management, with JoAnn ...  MD Magazine\", \"published date\": \"2023-12-07\", \"url\": \"https://news.google.com/rss/articles/CBMiWGh0dHBzOi8vd3d3LmhjcGxpdmUuY29tL3ZpZXcvZmV6b2xpbmV0YW50LW1lbm9wYXVzZS1tYW5hZ2VtZW50LWpvYW5uLXZlbnNrby1waW5rZXJ0b24tbWTSAQA?oc=5&hl=en-US&gl=US&ceid=US:en\", \"publisher.href\": \"https://www.hcplive.com\", \"publisher.title\": \"MD Magazine\", \"query end date\": \"2023-12-07T02:32:38.447734\", \"published datetime\": \"2023-12-07T02:26:04\", \"article text\": \"Earlier this year, the US Food and Drug Administration (FDA) approved fezolinetant (Veozah) for the treatment of moderate to severe vasomotor symptoms associated with menopause. The indication granted to Astellas Pharma in May marked the first neurokinin 3 receptor antagonist to reach the market for managing menopausal hot flashes.1\\n\\nReaction to the once-daily oral drug\\u2019s breakthrough approval among OB/GYN specialists was resonant of excitement for a novel mechanism of care to treat hot flashes\\u2014and relief for the market\\u2019s long-awaited expansion to include options like fezolinetant.2\\n\\nIn an interview with Contemporary OB/GYN assistant editor Celeste Krewson for This Year in Medicine 2023, JoAnn Vensko Pinkerton, MD, professor of obstetrics and gynecology at the University of Virginia and a credential menopause specialist with The Menopause Society, discussed the impact of fezolinetant\\u2019s FDA approval on menopause treatment. Chief among Pinkerton\\u2019s takeaways were the non-estrogen, non-hormonal makeup of fezolinetant\\u2014as well as her own personal experiences in prescribing the therapy.\\n\\nFezolinetant and Krewson additionally review the pivotal data from the SKYLIGHT trial program supporting fezolinetant, as well as anticipation for long-term utility and rollout of the agent to real-world patients in 2023 and beyond.\\n\\nReferences\", \"article summary\": \"Earlier this year, the US Food and Drug Administration (FDA) approved fezolinetant (Veozah) for the treatment of moderate to severe vasomotor symptoms associated with menopause.\\nThe indication granted to Astellas Pharma in May marked the first neurokinin 3 receptor antagonist to reach the market for managing menopausal hot flashes.1Reaction to the once-daily oral drug\\u2019s breakthrough approval among OB/GYN specialists was resonant of excitement for a novel mechanism of care to treat hot flashes\\u2014and relief for the market\\u2019s long-awaited expansion to include options like fezolinetant.2In an interview with Contemporary OB/GYN assistant editor Celeste Krewson for This Year in Medicine 2023, JoAnn Vensko Pinkerton, MD, professor of obstetrics and gynecology at the University of Virginia and a credential menopause specialist with The Menopause Society, discussed the impact of fezolinetant\\u2019s FDA approval on menopause treatment.\\nChief among Pinkerton\\u2019s takeaways were the non-estrogen, non-hormonal makeup of fezolinetant\\u2014as well as her own personal experiences in prescribing the therapy.\\nFezolinetant and Krewson additionally review the pivotal data from the SKYLIGHT trial program supporting fezolinetant, as well as anticipation for long-term utility and rollout of the agent to real-world patients in 2023 and beyond.\", \"article keywords.list.item\": \"2023\"}, \"maxValues\": {\"title\": \"Fezolinetant Changes Menopause Management, with JoAnn ... - MD Magazine\", \"description\": \"Fezolinetant Changes Menopause Management, with JoAnn ...  MD Magazine\", \"published date\": \"2023-12-07\", \"url\": \"https://news.google.com/rss/articles/CBMiWGh0dHBzOi8vd3d3LmhjcGxpdmUuY29tL3ZpZXcvZmV6b2xpbmV0YW50LW1lbm9wYXVzZS1tYW5hZ2VtZW50LWpvYW5uLXZlbnNrby1waW5rZXJ0b24tbWTSAQA?oc=5&hl=en-US&gl=US&ceid=US:en\", \"publisher.href\": \"https://www.hcplive.com\", \"publisher.title\": \"MD Magazine\", \"query end date\": \"2023-12-07T02:32:38.447734\", \"published datetime\": \"2023-12-07T02:26:04\", \"article text\": \"Earlier this year, the US Food and Drug Administration (FDA) approved fezolinetant (Veozah) for the treatment of moderate to severe vasomotor symptoms associated with menopause. The indication granted to Astellas Pharma in May marked the first neurokinin 3 receptor antagonist to reach the market for managing menopausal hot flashes.1\\n\\nReaction to the once-daily oral drug\\u2019s breakthrough approval among OB/GYN specialists was resonant of excitement for a novel mechanism of care to treat hot flashes\\u2014and relief for the market\\u2019s long-awaited expansion to include options like fezolinetant.2\\n\\nIn an interview with Contemporary OB/GYN assistant editor Celeste Krewson for This Year in Medicine 2023, JoAnn Vensko Pinkerton, MD, professor of obstetrics and gynecology at the University of Virginia and a credential menopause specialist with The Menopause Society, discussed the impact of fezolinetant\\u2019s FDA approval on menopause treatment. Chief among Pinkerton\\u2019s takeaways were the non-estrogen, non-hormonal makeup of fezolinetant\\u2014as well as her own personal experiences in prescribing the therapy.\\n\\nFezolinetant and Krewson additionally review the pivotal data from the SKYLIGHT trial program supporting fezolinetant, as well as anticipation for long-term utility and rollout of the agent to real-world patients in 2023 and beyond.\\n\\nReferences\", \"article summary\": \"Earlier this year, the US Food and Drug Administration (FDA) approved fezolinetant (Veozah) for the treatment of moderate to severe vasomotor symptoms associated with menopause.\\nThe indication granted to Astellas Pharma in May marked the first neurokinin 3 receptor antagonist to reach the market for managing menopausal hot flashes.1Reaction to the once-daily oral drug\\u2019s breakthrough approval among OB/GYN specialists was resonant of excitement for a novel mechanism of care to treat hot flashes\\u2014and relief for the market\\u2019s long-awaited expansion to include options like fezolinetant.2In an interview with Contemporary OB/GYN assistant editor Celeste Krewson for This Year in Medicine 2023, JoAnn Vensko Pinkerton, MD, professor of obstetrics and gynecology at the University of Virginia and a credential menopause specialist with The Menopause Society, discussed the impact of fezolinetant\\u2019s FDA approval on menopause treatment.\\nChief among Pinkerton\\u2019s takeaways were the non-estrogen, non-hormonal makeup of fezolinetant\\u2014as well as her own personal experiences in prescribing the therapy.\\nFezolinetant and Krewson additionally review the pivotal data from the SKYLIGHT trial program supporting fezolinetant, as well as anticipation for long-term utility and rollout of the agent to real-world patients in 2023 and beyond.\", \"article keywords.list.item\": \"virginia\"}, \"nullCount\": {\"title\": 0, \"description\": 0, \"published date\": 0, \"url\": 0, \"publisher.href\": 0, \"publisher.title\": 0, \"query end date\": 0, \"published datetime\": 0, \"article text\": 0, \"article html\": 0, \"article summary\": 0, \"article keywords.list.item\": 0}}","tags":null,"deletionVector":null,"baseRowId":null,"defaultRowCommitVersion":null,"clusteringProvider":null}}
{"add":{"path":"query=Ozempic%2520Eli%2520Lilly/published date str=2023-12-05/1-ee5c5e5b-1208-47ad-8fa1-99d2d50bb2d9-0.parquet","partitionValues":{"query":"Ozempic Eli Lilly","published date str":"2023-12-05"},"size":1367744,"modificationTime":1701916432940,"dataChange":true,"stats":"{\"numRecords\": 20, \"minValues\": {\"title\": \"Abnehmspritzen: Hoffnung f\\u00fcr \\u00dcbergewichtige oder nur Profit f\\u00fcr ... - Berliner Zeitung\", \"description\": \"Abnehmspritzen: Hoffnung f\\u00fcr \\u00dcbergewichtige oder nur Profit f\\u00fcr ...  Berliner Zeitung\", \"published date\": \"2023-12-05\", \"url\": \"https://news.google.com/rss/articles/CBMiKmh0dHBzOi8vd3d3LmZvcmJlc2NoaW5hLmNvbS9idXNpbmVzcy82NjQxMdIBAA?oc=5&hl=en-US&gl=US&ceid=US:en\", \"publisher.href\": \"https://de.tradingview.com\", \"publisher.title\": \"Barron's\", \"query end date\": \"2023-12-07T02:32:38.447734\", \"published datetime\": \"2023-12-05T05:00:59\", \"article text\": \"\", \"article summary\": \"\", \"article keywords.list.item\": \"2023\"}, \"maxValues\": {\"title\": \"\\u7f57\\u6c0f\\u5c06\\u4ee527\\u4ebf\\u7f8e\\u5143\\u6536\\u8d2d\\u80a5\\u80d6\\u548c\\u7cd6\\u5c3f\\u75c5\\u836f\\u7269\\u5236\\u9020\\u5546Carmot Therapeutics ... - \\u798f\\u5e03\\u65af\\u4e2d\\u56fd\", \"description\": \"\\u7f57\\u6c0f\\u5c06\\u4ee527\\u4ebf\\u7f8e\\u5143\\u6536\\u8d2d\\u80a5\\u80d6\\u548c\\u7cd6\\u5c3f\\u75c5\\u836f\\u7269\\u5236\\u9020\\u5546Carmot Therapeutics ...  \\u798f\\u5e03\\u65af\\u4e2d\\u56fd\", \"published date\": \"2023-12-05\", \"url\": \"https://news.google.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?oc=5&hl=en-US&gl=US&ceid=US:en\", \"publisher.href\": \"https://www.nasdaq.com\", \"publisher.title\": \"\\u798f\\u5e03\\u65af\\u4e2d\\u56fd\", \"query end date\": \"2023-12-07T02:32:38.447734\", \"published datetime\": \"2023-12-05T20:04:09\", \"article text\": \"\\u00a9 2023 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. \\\"Reuters\\\" and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.\", \"article summary\": \"We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits.\\nBy clicking \\u201cAccept All\\u201d, you consent to the use of ALL the cookies.\", \"article keywords.list.item\": \"\\u0444\\u0430\\u0440\\u043c\\u043e\\u0442\\u0440\\u0430\\u0441\\u043b\\u0438\"}, \"nullCount\": {\"title\": 0, \"description\": 0, \"published date\": 0, \"url\": 0, \"publisher.href\": 0, \"publisher.title\": 0, \"query end date\": 0, \"published datetime\": 0, \"article text\": 3, \"article html\": 3, \"article summary\": 3, \"article keywords.list.item\": 3}}","tags":null,"deletionVector":null,"baseRowId":null,"defaultRowCommitVersion":null,"clusteringProvider":null}}
{"add":{"path":"query=Ozempic%2520Eli%2520Lilly/published date str=2023-12-04/1-ee5c5e5b-1208-47ad-8fa1-99d2d50bb2d9-0.parquet","partitionValues":{"published date str":"2023-12-04","query":"Ozempic Eli Lilly"},"size":1703931,"modificationTime":1701916432968,"dataChange":true,"stats":"{\"numRecords\": 33, \"minValues\": {\"title\": \"1 in 3 Parents Interested in Weight Loss Drugs for Their Kids - Morning Consult\", \"description\": \"1 in 3 Parents Interested in Weight Loss Drugs for Their Kids  Morning Consult\", \"published date\": \"2023-12-04\", \"url\": \"https://news.google.com/rss/articles/CBMiKmh0dHBzOi8vd3d3Lm5wci5vcmcvdHJhbnNjcmlwdHMvMTE5Nzk1ODY5NdIBAA?oc=5&hl=en-US&gl=US&ceid=US:en\", \"publisher.href\": \"http://www.infostockdaily.co.kr\", \"publisher.title\": \"BioPharma-Reporter.com\", \"query end date\": \"2023-12-07T02:32:38.447734\", \"published datetime\": \"2023-12-04T10:30:00\", \"article text\": \"\", \"article html\": \"\", \"article summary\": \"\", \"article keywords.list.item\": \"2023\"}, \"maxValues\": {\"title\": \"\\uc2a4\\ud2f0\\ud3a0(Stifel), \\ube44\\ub9cc\\uc57d \\uc2dc\\uc7a5 \\uc99d\\uac00\\u2026\\uc758\\ub958 \\uad00\\ub828\\uc8fc\\uc5d0 \\ubbf8\\uce58\\ub294 \\uc601\\ud5a5\\uc740? - \\uc778\\ud3ec\\uc2a4\\ud0c1\\ub370\\uc77c\\ub9ac\", \"description\": \"\\uc2a4\\ud2f0\\ud3a0(Stifel), \\ube44\\ub9cc\\uc57d \\uc2dc\\uc7a5 \\uc99d\\uac00\\u2026\\uc758\\ub958 \\uad00\\ub828\\uc8fc\\uc5d0 \\ubbf8\\uce58\\ub294 \\uc601\\ud5a5\\uc740?  \\uc778\\ud3ec\\uc2a4\\ud0c1\\ub370\\uc77c\\ub9ac\", \"published date\": \"2023-12-04\", \"url\": \"https://news.google.com/rss/articles/CBMitgFodHRwczovL3d3dy56b25lYm91cnNlLmNvbS9jb3Vycy9hY3Rpb24vUk9DSEUtSE9MRElORy1BRy05MzY0OTc1L2FjdHVhbGl0ZS9Sb2NoZS1lbnRyZS1kYW5zLWxhLWNvdXJzZS1hdXgtbWVkaWNhbWVudHMtY29udHJlLWwtb2Jlc2l0ZS1hdmVjLWwtYWNxdWlzaXRpb24tZGUtQ2FybW90LXBvdXItMi03LTQ1NDkzOTE0L9IBAA?oc=5&hl=en-US&gl=US&ceid=US:en\", \"publisher.href\": \"https://www.zonebourse.com\", \"publisher.title\": \"\\uc778\\ud3ec\\uc2a4\\ud0c1\\ub370\\uc77c\\ub9ac\", \"query end date\": \"2023-12-07T02:32:38.447734\", \"published datetime\": \"2023-12-04T23:27:42\", \"article text\": \"\\uc0ac\\uc9c4=\\ub8f0\\ub8e8\\ub808\\ubaac \\uc560\\uc2ac\\ub808\\ud2f0\\uce74(Lululemon Athletica) \\ud68c\\uc0ac\\uc18c\\uac1c \\uad00\\ub828 \\uc774\\ubbf8\\uc9c0, LULU \\ud648\\ud398\\uc774\\uc9c0\\n\\n[\\uc778\\ud3ec\\uc2a4\\ud0c1\\ub370\\uc77c\\ub9ac=\\uc11c\\ub3d9\\ud658 \\uae30\\uc790] \\ubbf8\\uad6d\\uc758 \\uc885\\ud569\\uae08\\uc735\\ud68c\\uc0ac \\uc2a4\\ud2f0\\ud3a0(Stifel)\\uc740 \\ucd5c\\uadfc \\uc790\\uccb4 \\uc870\\uc0ac\\ub97c \\ud1b5\\ud574 \\uc810\\uc810 \\ub354 \\uc778\\uae30\\uac00 \\ub192\\uc544\\uc9c0\\uace0 \\uc788\\ub294 \\uccb4\\uc911\\uac10\\ub7c9 \\uc57d\\ubb3c\\uc740 \\uac1c\\uc778\\uc758 \\uccb4\\uc911\\uac10\\ub7c9\\uc744 \\ub3c4\\uc6b8\\ubfd0\\ub9cc \\uc544\\ub2c8\\ub77c \\uc18c\\ube44 \\ud2b8\\ub80c\\ub4dc, \\ud2b9\\ud788 \\uc758\\ub958\\uc5d0 \\uc601\\ud5a5\\uc744 \\ubbf8\\uce60 \\uc218 \\uc788\\ub2e4\\uace0 \\ubd84\\uc11d\\ud588\\ub2e4.\\n\\n\\uc18c\\ube44\\uc790\\ub97c \\ub300\\uc0c1\\uc73c\\ub85c \\ud55c \\uc2a4\\ud2f0\\ud3a0(Stifel)\\uc758 \\uc124\\ubb38\\uc870\\uc0ac\\uc5d0 \\ub530\\ub974\\uba74 \\uc751\\ub2f5\\uc790\\uc758 15%\\uac00 GLP-1 \\uc57d\\ubb3c\\uc744 \\ubcf5\\uc6a9\\ud558\\uace0 \\uc788\\ub294 \\uac83\\uc73c\\ub85c \\ub098\\ud0c0\\ub0ac\\ub2e4. \\uc774\\ub7ec\\ud55c \\uccb4\\uc911\\uac10\\ub7c9 \\uc57d\\ubb3c\\ub85c\\ub294 \\uc77c\\ub77c\\uc774 \\ub9b4\\ub9ac(Eli Lilly)\\uc758 \\ub9c8\\uc6b4\\uc790\\ub85c(Mounjaro)\\uc640 \\ub178\\ubcf4 \\ub178\\ub514\\uc2a4\\ud06c(Novo Nordisk)\\uc758 \\uc704\\uace0\\ube44(Wegovy) \\ubc0f \\uc624\\uc82c\\ud53d(Ozempic)\\uc774 \\uc788\\ub2e4.\\n\\n\\ud604\\uc7ac \\uc704\\uace0\\ube44(Wegovy)\\ub9cc\\uc774 \\uccb4\\uc911\\uac10\\ub7c9\\uc5d0 \\ub300\\ud55c \\ubbf8\\uad6d \\uc2dd\\ud488\\uc758\\uc57d\\uad6d(FDA) \\uc2b9\\uc778\\uc744 \\ubc1b\\uc558\\uc73c\\ub098, \\ub9c8\\uc6b4\\uc790\\ub85c(Mounjaro)\\ub3c4 \\uace7 \\uadf8 \\uc801\\uc751\\uc99d(indication)\\uc744 \\uc5bb\\uc744 \\uac83\\uc73c\\ub85c \\uc608\\uc0c1\\ub418\\uace0 \\uc788\\ub2e4. \\uc544\\uc6b8\\ub7ec \\uc2a4\\ud2f0\\ud3a0(Stifel)\\uc758 \\uc870\\uc0ac\\ub97c \\ud1b5\\ud574 \\ub610 \\ub2e4\\ub978 \\uc57d\\ubb3c\\uc774 \\ubbf8\\uad6d FDA \\uc2b9\\uc778\\uc744 \\uc5bb\\uc5b4 \\ud6a8\\uacfc\\uac00 \\uc785\\uc99d\\ub420 \\uacbd\\uc6b0 \\uc751\\ub2f5\\uc790\\uc758 21%\\uac00 \\ucd94\\uac00\\uc801\\uc73c\\ub85c GLP-1 \\uc57d\\ubb3c \\ubcf5\\uc6a9\\uc5d0 \\uad00\\uc2ec\\uc774 \\uc788\\ub294 \\uac83\\uc73c\\ub85c \\ub098\\ud0c0\\ub0ac\\ub2e4.\\n\\n\\uc774\\uc640 \\uad00\\ub828\\ud574 \\uc2a4\\ud2f0\\ud3a0(Stifel)\\uc758 \\uc9d0 \\ub354\\ud53c(Jim Duffy)\\ub294 GLP-1 \\ud655\\ub300\\uc758 \\uc7a0\\uc7ac\\uc801 \\uc218\\ud61c\\uc790\\ub85c \\ub8f0\\ub8e8\\ub808\\ubaac \\uc560\\uc2ac\\ub808\\ud2f0\\uce74(Lululemon Athletica Inc., NASDAQ:LULU), \\ub9ac\\ubc14\\uc774\\uc2a4(Levi Strauss & Co., NYSE:LEVI), \\ucf58\\ud22c\\uc5b4 \\ube0c\\ub79c\\uc988(Kontoor Brands, Inc., NYSE:KTB), \\ub515\\uc2a4 \\uc2a4\\ud3ec\\ud305 \\uad7f\\uc988(DICK'S Sporting Goods, Inc., NYSE:DKS)\\uc640 \\uac19\\uc740 \\uba87\\uba87\\uc758 \\uc18c\\ub9e4\\uc5c5\\uccb4\\ub97c \\uc5b8\\uae09\\ud588\\ub2e4.\\n\\n\\ub354\\ud53c\\ub294 \\ucd5c\\uadfc \\ud604\\uc9c0 \\ub9e4\\uccb4\\uc640\\uc758 \\uc778\\ud130\\ubdf0\\uc5d0\\uc11c \\\"\\uccb4\\uc911\\uac10\\ub7c9 \\uc57d\\ubb3c\\uc744 \\ubcf5\\uc6a9\\ud558\\uace0 \\uc0c1\\ub2f9\\ud55c \\uccb4\\uc911\\uc744 \\uac10\\ub7c9\\ud55c \\uc0ac\\ub78c\\ub4e4\\uc740 \\uc0c8 \\uc637\\uc774 \\ud544\\uc694\\ud558\\uba70, \\uc5f0\\uac04 \\ub450 \\ubc30\\uc758 \\uc758\\ub958\\ube44\\ub97c \\uc9c0\\ucd9c\\ud558\\uac8c \\ub420 \\uac83\\\"\\uc774\\ub77c\\uace0 \\uc804\\ub9dd\\ud55c \\ubc14 \\uc788\\ub2e4.\\n\\n\\ub610\\ud55c \\uc870\\uc0ac \\uacb0\\uacfc\\ub97c \\ubc14\\ud0d5\\uc73c\\ub85c \\ub354\\ud53c\\ub294 \\ub2e4\\ub978 \\uc0b0\\uc5c5 \\uc5ed\\uc2dc \\uccb4\\uc911\\uac10\\ub7c9 \\uc57d\\ubb3c \\uc0ac\\uc6a9 \\uc99d\\uac00\\ub85c \\uc774\\uc775\\uc744 \\uc5bb\\uc744 \\uc218 \\uc788\\ub2e4\\uace0 \\uc608\\uc0c1\\ud558\\uba70, \\\"GLP-1\\uc758 \\uc0ac\\uc6a9\\uc774 \\ubd80\\ubb38\\ubcc4\\ub85c \\uc5d0\\ub108\\uc9c0 \\uc74c\\ub8cc, \\uac04\\ud3b8 \\uc601\\uc591\\uc2dd, \\uce74\\ud14c\\uace0\\ub9ac\\ubcc4\\ub85c\\ub294 \\uc758\\ub958, \\uc561\\ud2f0\\ube0c \\ub77c\\uc774\\ud504\\uc2a4\\ud0c0\\uc77c \\uc601\\uc591(active lifestyle nutrition)\\uc774 \\uac00\\uc7a5 \\uc218\\ud61c\\ub97c \\ubc1b\\uc744 \\uac83\\\"\\uc774\\ub77c\\uace0 \\uc124\\uba85\\ud588\\ub2e4.\\n\\n\\n\\n-\\uad6d\\ub0b4 \\uae30\\uc5c5 \\uc5f0\\uad00 \\uc774\\uc288-\\n\\n\\uae00\\ub85c\\ubc8c \\ube44\\ub9cc\\uc57d \\uc2dc\\uc7a5\\uc744 \\uc0ac\\uc2e4\\uc0c1 \\ub178\\ubcf4\\ub178\\ub514\\uc2a4\\ud06c '\\uc704\\uace0\\ube44'\\uc640 \\ub0b4\\ub144 \\ubbf8\\uad6d \\uc2dd\\ud488\\uc758\\uc57d\\uad6d(FDA) \\uc2b9\\uc778\\uc744 \\uc55e\\ub454 \\uc77c\\ub77c\\uc774\\ub9b4\\ub9ac '\\ub9c8\\uc6b4\\uc790\\ub85c' \\ub4f1 \\uae00\\ub85c\\ubc8c \\uae30\\uc5c5\\uc774 \\ub3c5\\uc810\\ud558\\uace0 \\uc788\\ub294 \\uac00\\uc6b4\\ub370, \\uad6d\\ub0b4 \\uae30\\uc5c5\\uc740 \\uc784\\uc0c1 \\uc2dc\\ud5d8 \\uacc4\\ud68d\\uc744 \\ucd94\\uc9c4\\uc911\\uc774\\uac70\\ub098, \\uc0ac\\uc5c5\\ud611\\ub825 MOU\\ub97c \\uccb4\\uacb0\\ud558\\ub294 \\ud615\\ud0dc\\ub97c \\ubcf4\\uc774\\uace0 \\uc788\\ub2e4.\\n\\n\\ud55c\\ubbf8\\uc57d\\ud488\\uc758 \\uacbd\\uc6b0 23\\ub14410\\uc6d4 \\ube44\\ub9cc \\uce58\\ub8cc\\uc81c \\uc5d0\\ud398\\uae00\\ub808\\ub098\\ud0c0\\uc774\\ub4dc(\\uac1c\\ubc1c\\uba85 HM11260C) \\uc784\\uc0c1 3\\uc0c1 \\uc2dc\\ud5d8\\uacc4\\ud68d\\uc744 \\uc2dd\\ud488\\uc758\\uc57d\\ud488\\uc548\\uc804\\ucc98\\ub85c\\ubd80\\ud130 \\uc2b9\\uc778\\ubc1b\\uc558\\ub2e4. \\uc5d0\\ud398\\uae00\\ub808\\ub098\\ud0c0\\uc774\\ub4dc\\ub294 \\uccb4\\ub0b4\\uc5d0\\uc11c \\uc778\\uc290\\ub9b0 \\ubd84\\ube44\\uc640 \\uc2dd\\uc695 \\uc5b5\\uc81c\\ub97c \\ub3d5\\ub294 GLP-1 \\ud638\\ub974\\ubaac\\uc758 \\uc720\\uc0ac\\uccb4\\ub85c \\uc791\\uc6a9\\ud55c \\uac83\\uc73c\\ub85c \\uc54c\\ub824\\uc84c\\ub2e4.\\n\\n\\ucf54\\uc2a4\\ub2e5 \\uc0c1\\uc7a5\\uc0ac \\ud050\\ub77c\\ud2f0\\uc2a4\\ub294 \\ube44\\ub9cc\\uce58\\ub8cc\\uc81c \\uc704\\uace0\\ube44\\uc758 \\ubc14\\uc774\\uc624\\uc2dc\\ubc00\\ub7ec PG004 \\uacf5\\uc815 \\uac1c\\ubc1c\\uc744 \\uc644\\ub8cc\\ud55c \\ud3a9\\uc9c4\\uacfc \\uc7ac\\uc870\\ud569 \\ud3a9\\ud0c0\\uc774\\ub4dc \\uc758\\uc57d\\ud488\\uc758 \\uae30\\uc220 \\uac1c\\ubc1c \\ubc0f \\uc0dd\\uc0b0\\uc744 \\uc704\\ud55c \\uc5c5\\ubb34\\uc758 \\uc0ac\\uc5c5\\ud611\\ub825 MOU(\\uc591\\ud574\\uac01\\uc11c)\\ub97c \\uccb4\\uacb0 \\ud588\\ub2e4.\\n\\n\\uc77c\\ub3d9\\uc81c\\uc57d\\uc740 GLP-1 \\uc218\\uc6a9\\uccb4 \\uc791\\uc6a9\\uc81c \\uae30\\uc804\\uc758 \\ub300\\uc0ac\\uc131 \\uc9c8\\ud658 \\uc2e0\\uc57d \\ud6c4\\ubcf4\\ubb3c\\uc9c8 'ID110521156'\\ub97c \\uac1c\\ubc1c\\uc911\\uc774\\uba70, \\ud5a5\\ud6c4 \\uc81c2\\ud615 \\ub2f9\\ub1e8\\ubcd1, \\ube44\\ub9cc \\ub4f1\\uc744 \\ud0c0\\uae43\\uc73c\\ub85c \\ud558\\ub294 \\uacbd\\uad6c\\uc6a9 \\uc2e0\\uc57d\\uc73c\\ub85c \\uac1c\\ubc1c\\ud560 \\uacc4\\ud68d\\uc774\\ub2e4.\\n\\n\\uc11c\\ub3d9\\ud658 \\uae30\\uc790 oensh1@infostock.co.kr\\n\\n\\uc800\\uc791\\uad8c\\uc790 \\u00a9 \\uc778\\ud3ec\\uc2a4\\ud0c1\\ub370\\uc77c\\ub9ac \\ubb34\\ub2e8\\uc804\\uc7ac \\ubc0f \\uc7ac\\ubc30\\ud3ec \\uae08\\uc9c0\", \"article html\": \"<html style=\\\"height:100%\\\"><head><META NAME=\\\"ROBOTS\\\" CONTENT=\\\"NOINDEX, NOFOLLOW\\\"><meta name=\\\"format-detection\\\" content=\\\"telephone=no\\\"><meta name=\\\"viewport\\\" content=\\\"initial-scale=1.0\\\"><meta http-equiv=\\\"X-UA-Compatible\\\" content=\\\"IE=edge,chrome=1\\\"><script type=\\\"text/javascript\\\" src=\\\"/_Incapsula_Resource?SWJIYLWA=719d34d31c8e3a6e6fffd425f7e032f3\\\"></script><script src=\\\"/gus-Nighnes-Actis-new-such-in-my-gone-Retyre-as-\\\" async></script></head><body style=\\\"margin:0px;height:100%\\\"><iframe id=\\\"main-iframe\\\" src=\\\"/_Incapsula_Resource?SWUDNSAI=31&xinfo=9-41889419-0%20NNNN%20RT%281701916384383%20135%29%20q%280%20-1%20-1%200%29%20r%280%20-1%29%20B12%2814%2c0%2c0%29%20U18&incident_id=453001920125891419-206848412438835209&edet=12&cinfo=0e0000006e2c&rpinfo=0&cts=hO04EPXzs04qBcJOn9gL0WKRT1UZ2VaMWRUq5q1opEOdmzWUa6lqdY0jY20R%2fp0s&mth=GET\\\" frameborder=0 width=\\\"100%\\\" height=\\\"100%\\\" marginheight=\\\"0px\\\" marginwidth=\\\"0px\\\">Request unsuccessful. Incapsula incident ID: 453001920125891419-206848412438835209</iframe></body></html>\", \"article summary\": \"\\uc18c\\ube44\\uc790\\ub97c \\ub300\\uc0c1\\uc73c\\ub85c \\ud55c \\uc2a4\\ud2f0\\ud3a0(Stifel)\\uc758 \\uc124\\ubb38\\uc870\\uc0ac\\uc5d0 \\ub530\\ub974\\uba74 \\uc751\\ub2f5\\uc790\\uc758 15%\\uac00 GLP-1 \\uc57d\\ubb3c\\uc744 \\ubcf5\\uc6a9\\ud558\\uace0 \\uc788\\ub294 \\uac83\\uc73c\\ub85c \\ub098\\ud0c0\\ub0ac\\ub2e4.\\n\\uc774\\ub7ec\\ud55c \\uccb4\\uc911\\uac10\\ub7c9 \\uc57d\\ubb3c\\ub85c\\ub294 \\uc77c\\ub77c\\uc774 \\ub9b4\\ub9ac(Eli Lilly)\\uc758 \\ub9c8\\uc6b4\\uc790\\ub85c(Mounjaro)\\uc640 \\ub178\\ubcf4 \\ub178\\ub514\\uc2a4\\ud06c(Novo Nordisk)\\uc758 \\uc704\\uace0\\ube44(Wegovy) \\ubc0f \\uc624\\uc82c\\ud53d(Ozempic)\\uc774 \\uc788\\ub2e4.\\n\\ud604\\uc7ac \\uc704\\uace0\\ube44(Wegovy)\\ub9cc\\uc774 \\uccb4\\uc911\\uac10\\ub7c9\\uc5d0 \\ub300\\ud55c \\ubbf8\\uad6d \\uc2dd\\ud488\\uc758\\uc57d\\uad6d(FDA) \\uc2b9\\uc778\\uc744 \\ubc1b\\uc558\\uc73c\\ub098, \\ub9c8\\uc6b4\\uc790\\ub85c(Mounjaro)\\ub3c4 \\uace7 \\uadf8 \\uc801\\uc751\\uc99d(indication)\\uc744 \\uc5bb\\uc744 \\uac83\\uc73c\\ub85c \\uc608\\uc0c1\\ub418\\uace0 \\uc788\\ub2e4.\\n\\uc544\\uc6b8\\ub7ec \\uc2a4\\ud2f0\\ud3a0(Stifel)\\uc758 \\uc870\\uc0ac\\ub97c \\ud1b5\\ud574 \\ub610 \\ub2e4\\ub978 \\uc57d\\ubb3c\\uc774 \\ubbf8\\uad6d FDA \\uc2b9\\uc778\\uc744 \\uc5bb\\uc5b4 \\ud6a8\\uacfc\\uac00 \\uc785\\uc99d\\ub420 \\uacbd\\uc6b0 \\uc751\\ub2f5\\uc790\\uc758 21%\\uac00 \\ucd94\\uac00\\uc801\\uc73c\\ub85c GLP-1 \\uc57d\\ubb3c \\ubcf5\\uc6a9\\uc5d0 \\uad00\\uc2ec\\uc774 \\uc788\\ub294 \\uac83\\uc73c\\ub85c \\ub098\\ud0c0\\ub0ac\\ub2e4.\\n\\uc77c\\ub3d9\\uc81c\\uc57d\\uc740 GLP-1 \\uc218\\uc6a9\\uccb4 \\uc791\\uc6a9\\uc81c \\uae30\\uc804\\uc758 \\ub300\\uc0ac\\uc131 \\uc9c8\\ud658 \\uc2e0\\uc57d \\ud6c4\\ubcf4\\ubb3c\\uc9c8 'ID110521156'\\ub97c \\uac1c\\ubc1c\\uc911\\uc774\\uba70, \\ud5a5\\ud6c4 \\uc81c2\\ud615 \\ub2f9\\ub1e8\\ubcd1, \\ube44\\ub9cc \\ub4f1\\uc744 \\ud0c0\\uae43\\uc73c\\ub85c \\ud558\\ub294 \\uacbd\\uad6c\\uc6a9 \\uc2e0\\uc57d\\uc73c\\ub85c \\uac1c\\ubc1c\\ud560 \\uacc4\\ud68d\\uc774\\ub2e4.\", \"article keywords.list.item\": \"\\ud1b5\\ud574\"}, \"nullCount\": {\"title\": 0, \"description\": 0, \"published date\": 0, \"url\": 0, \"publisher.href\": 0, \"publisher.title\": 0, \"query end date\": 0, \"published datetime\": 0, \"article text\": 7, \"article html\": 7, \"article summary\": 7, \"article keywords.list.item\": 8}}","tags":null,"deletionVector":null,"baseRowId":null,"defaultRowCommitVersion":null,"clusteringProvider":null}}
{"add":{"path":"query=Ozempic%2520Eli%2520Lilly/published date str=2023-12-06/1-ee5c5e5b-1208-47ad-8fa1-99d2d50bb2d9-0.parquet","partitionValues":{"published date str":"2023-12-06","query":"Ozempic Eli Lilly"},"size":3204089,"modificationTime":1701916432978,"dataChange":true,"stats":"{\"numRecords\": 21, \"minValues\": {\"title\": \"B\\u00f6rse: Gesundheits-Aktien sind jetzt g\\u00fcnstig - und bleiben langfristig ein Kauf - FOCUS Online\", \"description\": \"B\\u00f6rse: Gesundheits-Aktien sind jetzt g\\u00fcnstig - und bleiben langfristig ein Kauf  FOCUS Online\", \"published date\": \"2023-12-06\", \"url\": \"https://news.google.com/rss/articles/CBMiRWh0dHBzOi8va2ZmaGVhbHRobmV3cy5vcmcvbW9ybmluZy1icmllZmluZy93ZWRuZXNkYXktZGVjZW1iZXItNi0yMDIzL9IBAA?oc=5&hl=en-US&gl=US&ceid=US:en\", \"publisher.href\": \"https://edition.cnn.com\", \"publisher.title\": \"BioSpace\", \"query end date\": \"2023-12-07T02:32:38.447734\", \"published datetime\": \"2023-12-06T00:16:00\", \"article text\": \"\", \"article summary\": \"\", \"article keywords.list.item\": \"2023\"}, \"maxValues\": {\"title\": \"Which Weight Loss Drug Is Best And Safest? Here's What Sets ... - Inverse\", \"description\": \"Which Weight Loss Drug Is Best And Safest? Here's What Sets ...  Inverse\", \"published date\": \"2023-12-06\", \"url\": \"https://news.google.com/rss/articles/CBMixgFodHRwczovL3d3dy53aWFkb21vc2NpaGFuZGxvd2UucGwva29uc3VtZW50LWktdHJlbmR5LXpha3Vwb3dlL296ZW1waWMtaS13ZWdvdnktd3N0cnphc25hLWhhbmRsZW0taS1wcnpldHdvcnN0d2VtLXp5d25vc2NpLWxla2ktb2RjaHVkemFqYWNlLW5vd2VqLWdlbmVyYWNqaS1tb2dhLW1vY25vLW5hbWllc3phYy13LWJyYW56eS1mbWNnLTI0OTgyOTjSAQA?oc=5&hl=en-US&gl=US&ceid=US:en\", \"publisher.href\": \"https://www.wiadomoscihandlowe.pl\", \"publisher.title\": \"northeastNOW\", \"query end date\": \"2023-12-07T02:32:38.447734\", \"published datetime\": \"2023-12-06T23:30:15\", \"article text\": \"\", \"article summary\": \"The popularity of anti-diabetes drugs like Ozempic and Mounjaro being repurposed for weight loss is soaring in the United States.\\nThe brand name delineates what the drug is being prescribed for: Mounjaro for Type 2 diabetes and Zepbound for weight loss.\\nHere\\u2019s everything you need to know about Zepbound and how it compares to the other weight loss drugs on the market.\\nFor weight loss, tirzepatide reduces appetite in two ways through GLP-1.\\nFor example, in an October 2022 study published in the journal Nature Medicine examining long-term weight loss effects, participants given a once-weekly injection of 2.4 milligrams of semaglutide experienced an average weight loss of 15 percent of their starting body weight.\", \"article keywords.list.item\": \"\\u017cywno\\u015bci\"}, \"nullCount\": {\"title\": 0, \"description\": 0, \"published date\": 0, \"url\": 0, \"publisher.href\": 0, \"publisher.title\": 0, \"query end date\": 0, \"published datetime\": 0, \"article text\": 0, \"article html\": 0, \"article summary\": 0, \"article keywords.list.item\": 0}}","tags":null,"deletionVector":null,"baseRowId":null,"defaultRowCommitVersion":null,"clusteringProvider":null}}
{"remove":{"path":"query=Ozempic%20Eli%20Lilly/published date str=2023-12-07/0-590aea05-cc70-41b0-acdd-2f6edf2e9588-0.parquet","dataChange":true,"deletionTimestamp":1701916432978,"extendedFileMetadata":false,"partitionValues":{"query":"Ozempic Eli Lilly","published date str":"2023-12-07"},"size":48833}}
{"remove":{"path":"query=Ozempic%20Eli%20Lilly/published date str=2023-12-06/0-590aea05-cc70-41b0-acdd-2f6edf2e9588-0.parquet","dataChange":true,"deletionTimestamp":1701916432978,"extendedFileMetadata":false,"partitionValues":{"published date str":"2023-12-06","query":"Ozempic Eli Lilly"},"size":223889}}
{"remove":{"path":"query=Ozempic%20Eli%20Lilly/published date str=2023-12-05/0-590aea05-cc70-41b0-acdd-2f6edf2e9588-0.parquet","dataChange":true,"deletionTimestamp":1701916432978,"extendedFileMetadata":false,"partitionValues":{"query":"Ozempic Eli Lilly","published date str":"2023-12-05"},"size":411792}}
{"commitInfo":{"timestamp":1701916432979,"operation":"WRITE","operationParameters":{"mode":"Overwrite","partitionBy":"[\"query\",\"published date str\"]"},"clientVersion":"delta-rs.0.17.0"}}